Amarin | AMRN - Ebitda

Amarin reported $2.2M in EBITDA for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Ebitda Change
Alnylam Pharmaceuticals ALNY:US USD -174303000 73.14M
Amarin AMRN:US USD 2.2M 39.04M
AstraZeneca AZN:LN USD 3.32B 283M
Esperion Therapeutics ESPR:US USD -42421000 903K
GlaxoSmithKline GSK:LN GBP 1.6B 1.76B
Halozyme Therapeutics HALO:US USD 83.06M 29.83M
Heron Therapeutics HRTX:US USD -41176000 7.65M
Intercept Pharmaceuticals ICPT:US USD -17884000 7.82M
IONIS PHARMACEUT IONS:US USD -204382000 149.65M
JAZZ PHA JAZZ:US USD -118655000 466.69M
Nektar Therapeutics NKTR:US USD -37707000 2.91M
Neurocrine Biosciences NBIX:US USD 107.8M 16M
Novartis NOVN:VX USD 4.5B 193M
Teva Pharmaceutical Industries TEVA:US USD 1.31B 245M